PIK3CA and vascular malformation: CYH33, another selective PI3Kα inhibitor, is being evaluated in a multicenter phase I/II study to assess its safety, tolerability, pharmacokinetics, and efficacy in patients with PROS and PIK3CA-related vascular malformations (PRVM), with results pending disclosure (CTR20231410).